Arthur Lahr is the founder of Avidicure. Avidicure has raised $50M in total funding. Latest round: Seed.
Arthur Lahr is the CEO and Co-Founder of Avidicure, a biotech company launched in April 2025 focusing on a multifunctional antibody modality for oncology. Avidicure secured $50 million in seed financing for its initial operations. Lahr previously held a leadership role at Crucell and Kiadis Pharma.
Full founder directory · Investor directory · Company funding database · Fundraising library